-
-
-
-
-
-
-
Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
-
-
-
-
-
-
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $85 at BofA Securities
-
-
-
-
-
-
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $94 at Bernstein
-
-
-
-
-
-
-
BioMarin expects $3.2 billion in 2025 revenue, ROCTAVIAN write-down
-
455,838 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

